Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)
NCT ID: NCT06480890
Last Updated: 2025-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
362 participants
OBSERVATIONAL
2024-07-02
2025-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting
NCT03627858
Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study
NCT05948891
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
NCT06234345
Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients
NCT03795350
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
NCT00465959
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged ≥40 years at BDP/FF/GB initiation
3. Had documented diagnosis of COPD prior to BDP/FF/GB initiation
4. Baseline CAT total score ≥10 (at the time of BDP/FF/GB initiation OR within the 12 weeks prior to treatment initiation, if no CAT total score is available on BDP/FF/GB initiation date)
5. Subjects who have initiated treatment with BDP/FF/GB within 12 weeks prior to informed consent form (ICF) signature, or on date of ICF signature
Exclusion Criteria
2. Subjects who are not likely to come back 12-weeks after BDP/FF/GB initiation, per Investigator judgement
3. Participation in any clinical trial in the 4 weeks prior to BDP/FF/GB initiation
4. Subjects had used any other single inhaler triple therapy before or at BDP/FF/GB initiation
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiesi Farmaceutici S.p.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinping Zheng, MD
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Guangzhou Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 156119 - Peking University People's Hospital
Beijing, Beijing Municipality, China
Site 156110 Beijing Jingmei Group Genetal Hospital
Beijing, Beijing Municipality, China
Site 156101 - The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site 156113 - The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site 156114 - The Second Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
Site 156108 - Henan Provincial People's Hospital
Zhengzhou, Henan, China
Site 156125 - Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Site 156117 - The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Site 156109 - Shandong Provincial Hospital
Jinan, Shandong, China
Site 156122 - Deyang People's Hospital
Deyang, Sichuan, China
Site 156102 - Mianyang Central Hospital
Mianyang, Sichuan, China
Site 156121 - The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang Uygur, China
Site 156106 - Huzhou Central Hospital
Huzhou, Zhejiang, China
Site 156115 - Jinhua Central Hospital
Jinhua, Zhejiang, China
Site 156124 - Lishui People's Hospital
Lishui, Zhejiang, China
Site 156112 - The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
Site 156103 - Shaoxing People's Hospital
Shaoxing, Zhejiang, China
Site 156105 - Taizhou Central Hospital
Taizhou, Zhejiang, China
Site 156123 - Wenling People's Hospital
Wenling, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTR20241876
Identifier Type: REGISTRY
Identifier Source: secondary_id
CLI-05993AA1-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.